{"organizations": [], "uuid": "6a62a0a8560885a22116701348d0f44b2f3a8f3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-psividas-second-phase-3-study-for/brief-psividas-second-phase-3-study-for-durasert-three-year-treatment-for-posterior-segment-uveitis-maintains-positive-efficacy-and-safety-profile-at-12-months-idUSFWN1PX1JP", "country": "US", "domain_rank": 408, "title": "BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.061, "site_type": "news", "published": "2018-02-08T05:51:00.000+02:00", "replies_count": 0, "uuid": "6a62a0a8560885a22116701348d0f44b2f3a8f3a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-psividas-second-phase-3-study-for/brief-psividas-second-phase-3-study-for-durasert-three-year-treatment-for-posterior-segment-uveitis-maintains-positive-efficacy-and-safety-profile-at-12-months-idUSFWN1PX1JP", "ord_in_thread": 0, "title": "BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "psivida corp", "sentiment": "neutral"}, {"name": "brief-psivida", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 7 (Reuters) - Psivida Corp:\n* PSIVIDA‘S SECOND PHASE 3 STUDY FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS MAINTAINS POSITIVE EFFICACY AND SAFETY PROFILE AT 12 MONTHS\n* PSIVIDA CORP - HIGHLY SIGNIFICANT DIFFERENCE BETWEEN DURASERT AND SHAM IN PREVENTION OF UVEITIS RECURRENCE AT 12 MONTHS IN STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T05:51:00.000+02:00", "crawled": "2018-02-09T06:07:40.002+02:00", "highlightTitle": ""}